Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Virax Biolabs GroupVRAX -8.33%45 EV-to-FCF is 0.76 as of Aug. 22, 2026, which is 138% above its 10-year median of 0.32. GuruFocus rates VRAX with a GF Score™ of 45/100 and a GF Value™ of $3.57 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 321 Biotechnology companies, Virax Biolabs Group ranks better than 83.8% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Virax Biolabs Group's Enterprise Value is $-3.72 Mil.
Virax Biolabs Group's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-4.88 Mil. Therefore, Virax Biolabs Group's EV-to-FCF for today is 0.76.
The historical rank and industry rank for Virax Biolabs Group's EV-to-FCF or its related term are showing as below:
VRAX'
s EV-to-FCF Range Over the Past 10 Years
Min: -208.26 Med: 0.32 Max: 1.99
Current: 0.76
During the past 7 years, the highest EV-to-FCF of Virax Biolabs Group was 1.99. The lowest was -208.26. And the median was 0.32.
VRAX's EV-to-FCF is ranked better than 83.8% of 321
companies
in the Biotechnology industry
Industry Median: 16.05
vs VRAX: 0.76
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Virax Biolabs Group (NAS:VRAX) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Virax Biolabs Group's PE Ratio (TTM) for today is calculated as:
Virax Biolabs Group's share price for today is $3.195.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Virax Biolabs Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-16.886.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Virax Biolabs Group EV-to-FCF Related Terms
Virax Biolabs Group EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Virax Biolabs Group's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Virax Biolabs Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virax Biolabs Group EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Virax Biolabs Group's EV-to-FCF falls into.
Virax Biolabs Group's current Enterprise Value is $-3.72 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Virax Biolabs Group's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-4.88 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Virax Biolabs Group (VRAX) has a EV-to-FCF of 0.76 as of Aug. 22, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Virax Biolabs Group and its competitors. This is 138% above median its historical median of 0.32. According to the industry distribution chart, Virax Biolabs Group ranks #52 out of 321 companies in the Biotechnology industry, placing it in the top 16.2%.
Is Virax Biolabs Group's EV-to-FCF too high?
Virax Biolabs Group's current EV-to-FCF of 0.76 is 138% above median its 10-year median of 0.32. The Biotechnology industry median EV-to-FCF is 16.05. Virax Biolabs Group's value of 0.76 is 95.3% below this industry median. Based on the distribution chart, Virax Biolabs Group ranks #52 out of 321 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Virax Biolabs Group has a GF Score™ of 45/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's EV-to-FCF compare to ISCO and PKTX?
According to the Biotechnology industry distribution chart, Virax Biolabs Group ranks #52 out of 321 companies for EV-to-FCF. This places Virax Biolabs Group in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 16.05. Virax Biolabs Group's value of 0.76 is 95.3% below this benchmark. While the company's 10-year median is 0.32 vs. the industry median of 16.05, Virax Biolabs Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.05, based on 321 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Virax Biolabs Group's current EV-to-FCF of 0.76 is 95.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Virax Biolabs Group and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Virax Biolabs Group's current EV-to-FCF is 0.76, which is 138% above median its own 10-year median of 0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.57, compared to a current price of $3.20 — trading 10.5% below its estimated fair value. The current EV-to-FCF is 0.76, which is 138% above median its 10-year median of 0.32 and 95.3% below the Biotechnology industry median of 16.05. Virax Biolabs Group's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current EV-to-FCF is 0.76 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virax Biolabs Group (VRAX) Overvalued in 2026?
Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be undervalued.
The current stock price of $3.20 is trading 10.5% below its estimated GF Value™ of $3.57.
GuruFocus considers Virax Biolabs Group to be Modestly Undervalued.
Key valuation signals for VRAX:
EV-to-FCF: 0.76 (138% above median its 10-year median of 0.32)
GF Value™: $3.57 vs. price of $3.20 (10.5% below fair value)
Industry Position: 95.3% below the Biotechnology median (#52 of 321)
No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
45GF Score
Get the complete analysis for VRAX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRAX has been successfully added to your 
